Vaccine shortages: History, impact, and prospects for the future

Annual Review of Public Health

Volumn 27, Issue , 2006, Pages 235-259

  Hinman, Alan R ^a   Orenstein, Walter A ^b   Santoli, Jeanne M ^c   Rodewald, Lance E ^c   Cochi, Stephen L ^c  

^a Task Force for Child Survival and Development   (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

Health policy; Immunization; Liability; Vaccine manufacture

Indexed keywords

BOTULINUM TOXOID; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; DIPHTHERIA TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; ORAL POLIOMYELITIS VACCINE; PEDIATRIX; PLAGUE VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; SMALLPOX VACCINE; TOXOID; UNCLASSIFIED DRUG; VACCINE; VARICELLA ZOSTER VACCINE; VENEZUELAN EQUINE ENCEPHALITIS VACCINE; VIRUS VACCINE; WART VIRUS VACCINE; WEST NILE VACCINE;

ADVERSE DRUG REACTION; CLINICAL TRIAL; DEVELOPING COUNTRY; DIPHTHERIA; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; EPIDEMIC; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH PROGRAM; HERPES ZOSTER; HUMAN; IMMUNIZATION; INFLUENZA; INFORMATION SERVICE; LEGAL LIABILITY; MEASLES; PATENT; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; PROFIT; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; TETANUS; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VACCINE SHORTAGE; VIRUS INFECTION;

COMMUNICABLE DISEASE CONTROL; DRUG INDUSTRY; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; UNITED STATES; VACCINES;

EID: 33144467044     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.27.021405.102248     Document Type: Review

References (63)

1. Auerbach S. 1976. States low in polio vaccine. Washington Post. Sept. 14, pp. A1, A8
2. Cent. Dis. Control Prev. 2003. Influenza vaccination coverage among adults aged ≥50 years and pneumococcal vaccination coverage among adults aged ≥65 years-United States, 2002. MMWR 52:987-92
3. Cent. Dis. Control Prev. 2004. Influenza and pneumococcal vaccination coverage among persons aged ≥65 years and persons aged 18-64 years with diabetes or asthma-United States, 2003. MMWR 53:1007-12
4. Cent. Dis. Control Prev. 2004. National, state, and urban area vaccination levels among children aged 19-35 months-United States, 2003. MMWR 53:658-61
5. Cent. Dis. Control Prev. 2004. Recommended adult immunization schedule-United States, October 2004-September 2005. MMWR 53:Q1-4
6. Cent. Dis. Control Prev. 2004. Interim influenza vaccination recommendations, 2004-2005 influenza season. MMWR 53:923-24
7. Cent. Dis. Control Prev. 2004. Vaccination coverage among children entering school-United States, 2003-04 school year. MMWR 53:1041-44
8. Cent. Dis. Control Prev. 2005. CDC vaccine price list. www.cdc.gov/nip/vfc/cdc_vac_price_list.pdf
9. Cent. Dis. Control Prev. 2005. Estimated influenza vaccination coverage among adults and children-United States, September 1, 2004-January 31, 2005. MMWR 54:304-7
10. Cent. Dis. Control Prev. 2005. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 54(RR07):1
11. Cent. Medicare/Medicaid Serv. 2005. Medicare announces new preventive benefits and physician payment increases in final physician payment rule for 2005. http://www.cms.hhs.gov/media/press/release.asp?Counter=1248
12. Chu SY, Barker LE, Smith PJ. 2004. Racial/ethnic disparities in preschools immunizations: United States, 1996-2001. Am. J. Public Health 94(6):973-77
13. Cohen S. 2002. U.S. vaccine supply falls seriously short. Science 295:1998-2001
14. Coleman MS, Sangrujee N, Zhou F, Chu S. 2005. Factors affecting U.S. manufacturers' decisions to produce vaccines. Health Aff. 24:635-42
15. Danzon P, Sousa Pereira N. 2005. Why sole-supplier vaccine markets may be here to stay. Health Aff. 2005:694-96
16. Dep. Health Hum. Serv. 2004. Pandemic influenza preparedness and response plan. http://www.hhs.gov/nvpo/pandemicplan/
17. Dowdle WR, Millar JD. 1978. Swine influenza: lessons learned. Med. Clin. North Am. 62:1047-57
18. FDA. 2005. Vaccines licensed for immunization and distributed in the United States. http://www.fda.gov/cber/vaccine/licvacc.htm
19. FDA. 2005. First combination vaccine approved to help protect adolescents against whooping cough. http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01354. html
20. FDA. 2005. FDA approves a new combination vaccine to help protect both adolescents and adults against whooping cough. http://www.fda.gov/bbs/topics/ ANSWERS/2005/ANS01361.html
21. Goodman JL. 2005. Statement before the Committee on Energy and Commerce, U.S. House Represent., May 4. http://www.fda.gov/ola/2005/influenza0504.html
22. Hanson MS, Edelman R. 2003. Progress and controversy surround vaccines against Lyme disease. Expert Rev. Vaccines 2:683-703
23. Harper DM, France EL, Wheeler C, Ferris DG, Jenkins D, et al. 2004. Efficacy of a bivalent L-1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 364:1757-65
24. Heaton PM. 2005. Merck Research Laboratories, PRV Safety/Efficacy trial. Presented to the Advis. Comm. Immun. Pract., Feb. 10-11. http://www.cdc.gov/nip/ acip/minutes/acip-min-feb05.rtf
25. Heinrich J. 2004. Flu Vaccine-Recent Supply Shortages Underscore Ongoing Challenges. Washington, DC: GAO. GAO-05-177T
26. Hinman AR. 1972. Resurgence of measles in New York. Am. J. Public Health 62:498-502
27. Hinman AR. 1986. DTP vaccine litigation. Am. J. Dis. Child. 140:528-30
28. st century: National Vaccine Advisory Committee/National Vaccine Program Office follow-up. http://www.dhhs.gov/nvpo/ nvac/NVAC-IOM100604.htm
29. Hinman AR, Orenstein WA, Rodewald L. 2004. Financing immunizations in the United States. Clin. Infect. Dis. 38:1440-46
30. Iglehart JK, ed. 2005. The vaccine enterprise. Health Aff. 24:594-769
31. Inst. Med. 2000. Calling the Shots: Immunization Finance Policies and Practices. Washington, DC: Natl. Acad.
32. st Century: Assuring Access and Availability. Washington, DC: Natl. Acad.
33. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-51
34. Murray R. 1969. Production and testing in the USA of influenza virus vaccine made from the Hong Kong variant in 1968-69. Bull. WHO 41:495-96
35. Natl. Inst. Allergy Infect. Dis. 2002. The Jordan Report 20th anniversary: accelerated development of vaccines 2002. http://www.niaid.nih.gov/ dmid/vaccines/jordan20/default.htm
36. Natl. Vaccine Advis. Comm. 1991. The measles epidemic: the problems, barriers, and recommendations. JAMA 266:1547-52
37. Natl. Vaccine Advis. Comm. 2003. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee. JAMA 290:3122-28
38. Natl. Vaccine Advis. Comm. 2005. Proc. Workshop on Strengthening the Supply of Vaccines in the United States, 2nd. Draft rep. presented to the Natl. Vaccine Advis. Comm., June 7
39. Offit PA. 2005. Why are pharmaceutical companies gradually abandoning vaccines? Health Aff. 24:622-30
40. Orenstein WA. 2002. Immunization and health disparity issues: implications for the United States. In A Report on Reaching Underserved Ethnic and Minority Populations to Improve Pediatric Immunization Rates, pp. 7-9. Washington, DC: Natl. Found. Infect. Dis.
41. Orenstein WA, Douglas RG, Rodewald LE, Hinman AR. 2005. Immunizations in the United States: success, structure, and stress. Health Aff. 24:599-610
42. Orenstein WA, Rodewald LE, Hinman AR. 2004. Immunization in the United States. In Vaccines, SA Plotkin, WA Orenstein, pp. 1359-65. Philadelphia: Elsevier. 4th ed.
43. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, et al. 2005. A vaccine to prevent herpes zoster and post herpetic neuralgia in older adults. N. Engl. J. Med. 352:2271-84
44. Partnersh. Prevent. 2005. Strengthening adult immunization: a call to action. http://www.prevent.org/docs/CalltoAction.pdf
45. Peter G, des Vignes-Kendrick M, Eickhoff TC, Fine A, Galvin V, et al. 1999. Lessons learned from a review of the development of selected vaccines: National Vaccine Advisory Committee. Pediatrics 104:942-50
46. Pickering LK, Orenstein WA. 2002. Development of pediatric vaccine recommendations and policies. Semin. Pediatr. Inf. Dis. 13:148-54
47. Plotkin SA. 2005. Why certain vaccines have been delayed or not developed at all. Health Aff. 24:631-34
48. Poland GA, Shefer AM, McCauley M, Webster PS, Whitley-Williams PN, Peter G. 2003. Standards for adult immunization practices. Am. J. Prev, Med. 25:144-50
49. Robinson CA, Sepe SJ, Lin KF. 1993. The president's child immunization initiative-a summary of the problem and the response. Public Health Rep. 108(4):419-25
50. Rosenthal J, Raymond D, Morita J, et al. 2002. African-American children are at risk of a measles outbreak in an inner-city community of Chicago, 2000. Am. J. Prev. Med. 23(3):195-99
51. Ruch-Ross HS, O'Connor KG. 1994. Immunization referral practices of pediatricians in the United States. Pediatrics 94(4 Pt. 1):508-13
52. Salisbury DM. 2005. Development of immunization policy and its implementation in the United Kingdom. Health Aff. 24:744-54
53. Santoli JM. 2005. Influenza vaccine supply and distribution: an overview of the 2004-2005 season. Presented to the Natl. Vaccine Advis. Comm., June 7
54. Santoli JM, Klein JO, Peter G, Orenstein WA. 2004. Disruptions in the supply of routinely recommended childhood vaccines in the United States. Pediatr. Infect. Dis. J. 23:553-54
55. Santoli JM, Setia S, Rodewald LE, O'Mara D, Gallo B, Brink E. 2000. Immunization pockets of need: science and practice. Am. J. Prev. Med. 19(3 Suppl. S):89-98
56. Santoli JM, Szilagyi PG, Rodewald LE. 1998. Barriers to immunization and missed opportunities. Pediatr. Ann. 27(6):366-74
57. Schulte JM, Brown GR, Zetzman MR, Schwartz B, Green G, et al. 1991. Changing immunization referral patterns among pediatricians and family practice physicians, Dallas County, Texas, 1988. Pediatrics 87(2):204-7
58. Secur. Exch. Comm. 1999. SEC staff accounting bulletin No. 101-revenue recognition in financial statements, Dec. http://www.sec.gov/interps/account. shtml
59. Sing M, Willian MK. 1996. Supplying vaccines: an overview of the market and regulatory context. In Supplying Vaccines: An Economic Analysis of Critical Issues, ed. MV Pauly, CA Robinson, SJ Sepe, M Sing, MK Willian, pp. 45-100. Washington, DC: IOS
60. Stein CR, Wortley PM, Singleton JA. 2003. Racial/ethnic disparities in influenza and pneumococcal vaccination levels among persons aged ≥65 years-United States, 1989-2001. MMWR 52:958-62
61. Stokley S, Santoli JM, Willis B, Kelley V, Vargas-Rosales A, Rodewald LE. 2004. Impact of vaccine shortages on immunization programs and providers. Am. J. Prev. Med. 26:15-21
62. Tomich N. 2003. The global vaccine shortage: the threat to children and what to do about it. http://www.sabin.org
63. Zimmerman RK, Medsger AR, Ricci EM, Raymund M, Mieczkowski TA, Grufferman S. 1997. Impact of free vaccine and insurance status on physician referral of children to public vaccine clinics. JAMA 278(12):996-1000